• The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ: SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric patients nine years of age and older.

• Twyneo uses Sol-Gel's patented technology to entrap tretinoin, a retinoid, and benzoyl peroxide within silica-based microcapsules to stabilize tretinoin from being degraded by benzoyl peroxide and to release each of the active drug ingredients slowly.

• The product is patent-protected until 2038.

• Sol-Gel has partnered with Galderma to commercialize Twyneo in the U.S.

• Sol-Gel expects to receive a regulatory milestone payment in conjunction with the approval.

• Price Action: SLGL shares are up 2.56% at $12.42 during the market session on the last check Tuesday.

• Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

• Click here for options trades from Benzinga

• AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine Candidate

• Relmada's Stock Moves Higher As Its Major Depressive Disorder Candidate Shows Lack Of Abuse Potential

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.